Table 5 Mutation detection in ctDNA by real-time PCR and MS approaches
From: Molecular profiling of lung cancer specimens and liquid biopsies using MALDI-TOF mass spectrometry
Patients with EGFR/KRAS mutated tumors | Mutation in FFPE tumors (mutated allele percentage) | Mutation detection in ctDNA by real-time PCR (ΔCt values) | Mutation detection in ctDNA by MS (mutated allele percentage) |
|---|---|---|---|
1 | EGFR L858R (56%) | D (2.55) | EGFR L858R (7%) |
2 | EGFR E746_A750delELREA (27%) | D (1.44) | EGFR E746_A750delELREA (5%) |
3 | EGFR E746_A750delELREA (60%) | D (3.66) | EGFR E746_A750delELREA (12%) |
4 | EGFR E746_A750delELREA (55%) | D (3) | EGFR E746_A750delELREA (19%) |
5 | EGFR E746_E750delELREA (50%) | D (4.02) | ND |
6 | EGFR E746_A750delELREA (30%) | ND (12.61) | ND |
7 | EGFR E746_A750delELREA (30%) | ND (14.03) | ND |
8 | EGFR L858R (18%) | ND (18.99) | ND |
9 | KRAS G12Â V (50%) | ND (27.23) | ND |
10 | KRAS G12Â V (41%) | ND (18.78) | ND |
11 | KRAS G12C (17%) | ND (19.63) | ND |
12 | KRAS G12Â V (33%) | ND (27.23) | ND |
13 | KRAS G12C (20%) | ND (16.95) | ND |